Allarity Therapeutics enters $6M equity line of credit with Tumim Stone Capital

Allarity Therapeutics, Inc.

Company may sell up to $6M of common stock at 95-97% of VWAP discount.
Commitment fee of $45,000 paid to investor upon execution.
Shares subject to Exchange Cap (19.99% of outstanding) unless stockholder waiver obtained.
Company must seek stockholder approval at next annual meeting to waive Exchange Cap.
Investor cannot own more than 4.99% (or 9.99% at its election) of outstanding shares.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Allarity Therapeutics, Inc. entered into Common Stock Purchase Agreement with Tumim Stone Capital LLC (effective 2026-01-28).

Action: entry
Agreement: equity purchase
Counterparty: Tumim Stone Capital LLC
Effective: 2026-01-28

Exact text from the filing

On January 28, 2026, Allarity Therapeutics, Inc. (the “ Company ”) entered into a Common Stock Purchase Agreement (the “ Purchase Agreement ”) with Tumim Stone Capital LLC, a Delaware limited liability company (the “ Investor ”).

View on SEC.gov

273 material agreements filed in the last 30 days. Browse all material agreements →

Allarity Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-009157

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.